Media Center
A multimedia mosaic of moments at GIST
GIST Excellence
[News Release] Professor Sung-Gyoo Park"s research team develops cell differentiation technology that can be used to treat inflammatory diseases
- 엘리스 리
- REG_DATE : 2017.01.13
- HIT : 1054
Professor Sung-Gyoo Park"s research team develops cell differentiation technology that can be used to treat inflammatory diseases
Immunoregulatory T cells regulate TGF-b-mediated immune-mediated cell differentiation and function. When the function of immunoregulatory T cells weakens or disappears, immune-mediated myelogenous differentiation from hematopoietic stem cells does not occur normally. In such an abnormal state, immunoregulatory myeloid cells with differentiated functions are differentiated and the positive feedback on immunoregulatory T cells is reduced. However, in the normal inflammatory reaction, immunoregulatory T cells supply TGF-b, resulting in normal immune-mediated myeloid differentiation, and positive feedbacks on immunoregulatory T cells by differentiated cells, effectively controlling inflammation.
□ The Gwangju Institute of Science and Technology (GIST • President Seung Hyeon Moon) announced that a research team led by Professor Professor Sung-Gyoo Park of the School of Life Sciences has developed immunocontrol myeloid cell differentiation technology by using hematopoietic stem cells to control of inflammatory diseases.
○ This research was supported by the Cell Logistics Research Center (Director Jang-Soo Chun), the Ministry of Science, ICT and Future Planning, and the Ministry of Health and Welfare.
○ The results of the study were published in the online edition of Cell Reports on December 20, 2016, with special recognition of the academic achievement.
□ Professor Park"s research team effectively controlled the development of inflammation within the body by improving the function of immune control T cells in the differentiation process and by improving immunoregulatory T cell functions by developing a technique to add hematopoietic stem cells to the immune-controlling bone marrow cells by adding a cytokine called TGF-β.
Through this process, the immune control function of the differentiated cells was greatly improved, and the immune control bone marrow cells differentiated from hematopoietic stem cells could control the inflammation.
□ Professor Sung-Gyoo Park said, "Through this research, we have built a foundation for the development of therapeutic approaches for patients with chronic inflammatory diseases, such as autoimmune diseases."
The results of this study are expected to be a cornerstone for the future development of therapeutic drugs and therapeutic strategies for autoimmune diseases without extensive, prolonged treatment.